Adv therap: artificial intelligence assisted treatment of metastatic prostate cancer, with significant effect

September 5, 2018 news / BIOON / - combined chemotherapy is a milestone on the road of cancer treatment, but optimizing its efficacy requires dose and time-dependent adjustment of drug synergy Traditional adjustment methods based on experiments are time-consuming and labor-consuming, with extremely low efficiency, which hinders the development of the best combination therapy Photo source: for this purpose, advanced therapeutics researchers have recently developed a platform based on artificial intelligence (AI) - curate AI to improve and accelerate this process In their study, the researchers used two drugs, the bromine domain inhibitor zen-3694 and the androgen receptor antagonist enzalutamide, as model drugs, and used this new AI platform to guide the combination of them in the treatment of a metastatic castrated resistant prostate cancer patient, aiming to reduce the prostate specificity in the patient's serum Antigen (PSA) The results showed that the best dosage of zen-3694 and enzalutamide was successfully found by curate.ai, which improved the efficacy and tolerance of the combination therapy In addition, curate.ai's analysis confirmed that the patient's sustained response originated from zen-3694 in the treatment regimen Because the cure.ai improves the therapeutic effect and patient tolerance, the patient can continue to use drugs, resulting in a sustained response At the same time, based on the control of the PSA level by cure.ai, the cancer will not progress, and even the tumor area will decrease This research result was recently published in advanced therapeutics, entitled "modeling bet bromodomain inhibitor zen-3694 and enchalutamine combination doing in a metastatic prostate cancer patient using cure.ai, an artistic intelligence platform" The research team hopes to expand the application of this platform to the prevention of transplant rejection, adult and pediatric cancer, cardiovascular disease and diabetes management, infectious diseases and many other medical fields Reference materials: Allan J pantuck et al, modulating bet bromodomain inhibitor zen-3694 and enzalutamide combination doing in a metastatic prostate cancer patient using cure.ai, an artistic intelligence platform, advanced therapeutics (2018) Doi: 10.1002/adtp.201800104